AIM
CTMX icon

Assured Investment Management’s CytomX Therapeutics CTMX Stock Holding History

Assured Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-33,864
Closed -$364K – 228
2019
Q1 		$364K Sell
33,864
-7,041
-17% -$104K ﹤0.01% 670
2018
Q4 		$618K Buy
40,905
+7,589
+23% +$113K 0.02% 589
2018
Q3 		$616K Sell
33,316
-2,382
-7% -$54.3K 0.01% 700
2018
Q2 		$816K Buy
35,698
+6,905
+24% +$176K 0.02% 634
2018
Q1 		$819K Buy
+28,793
New +$822K 0.02% 612

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Assured Investment Management's CTMX Position: Q2 2019 in Review

Assured Investment Management sold out of CytomX Therapeutics (CTMX) in Q2 2019, closing a stake of 33,864 shares — an estimated $364K sold.

Assured Investment Management first reported a position in CTMX in Q1 2018 and held it in 5 quarters. The position peaked at $819K in Q1 2018. 109 funds tracked by Wall St. Rank hold CTMX as of Q2 2019.

  • Assured Investment Management reported no remaining CytomX Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Assured Investment Management sold 33,864 CytomX Therapeutics shares in Q2 2019, an estimated $364K.
  • Assured Investment Management first reported a position in CytomX Therapeutics in Q1 2018 and held it in 5 quarters.
  • Assured Investment Management's CytomX Therapeutics position peaked at $819K in Q1 2018.
  • 109 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2019.

Based on Assured Investment Management's 13F filing for Q2 2019, filed 14 Aug 2019.